SK284029B6 - Farmaceutická kompozícia na liečenie roztrúsenej sklerózy - Google Patents

Farmaceutická kompozícia na liečenie roztrúsenej sklerózy Download PDF

Info

Publication number
SK284029B6
SK284029B6 SK931-99A SK93199A SK284029B6 SK 284029 B6 SK284029 B6 SK 284029B6 SK 93199 A SK93199 A SK 93199A SK 284029 B6 SK284029 B6 SK 284029B6
Authority
SK
Slovakia
Prior art keywords
copolymer
cells
eae
day
fed
Prior art date
Application number
SK931-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK93199A3 (en
Inventor
Ruth Arnon
Michael Sela
Dvora Teitelbaum
Adrian Gilbert
Milka Linenberg
Rivka Riven-Kreitman
Original Assignee
Yeda Research And Development Co., Ltd-Company Of Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co., Ltd-Company Of Israel filed Critical Yeda Research And Development Co., Ltd-Company Of Israel
Publication of SK93199A3 publication Critical patent/SK93199A3/sk
Publication of SK284029B6 publication Critical patent/SK284029B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
SK931-99A 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy SK284029B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (2)

Publication Number Publication Date
SK93199A3 SK93199A3 (en) 2000-11-07
SK284029B6 true SK284029B6 (sk) 2004-08-03

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
SK931-99A SK284029B6 (sk) 1997-01-10 1998-01-12 Farmaceutická kompozícia na liečenie roztrúsenej sklerózy

Country Status (19)

Country Link
EP (1) EP0975351B1 (de)
JP (1) JP4216342B2 (de)
KR (1) KR20000070058A (de)
CN (1) CN100528222C (de)
AT (1) ATE356608T1 (de)
AU (1) AU737287B2 (de)
BR (1) BRPI9807076B8 (de)
CA (1) CA2277365C (de)
CZ (1) CZ297983B6 (de)
DE (1) DE69837324T2 (de)
EA (1) EA003128B1 (de)
HK (1) HK1025737A1 (de)
HU (1) HU226612B1 (de)
IL (2) IL119989A0 (de)
NZ (1) NZ336690A (de)
PL (1) PL193300B1 (de)
SK (1) SK284029B6 (de)
WO (1) WO1998030227A1 (de)
ZA (1) ZA98214B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105414A2 (de) * 1998-07-23 2001-06-13 President And Fellows of Harvard College Kunstliche peptide und deren verwendungen für therapie gegen autoimmunkrankenheiten
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
ES2235896T3 (es) * 1999-06-04 2005-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Uso de riluzol para el tratamaiento de la esclerosis multiple.
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
DE60120648D1 (de) * 2000-02-18 2006-07-27 Yeda Res & Dev Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
EP1292279A4 (de) * 2000-06-05 2005-01-12 Teva Pharma Verwendung von glatiramer acetat (copolymer 1) zur behandlung von störungen des zentralen nervensystems
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
SK50642005A3 (sk) * 2003-01-24 2006-02-02 Elan Pharmaceuticals, Inc. Kompozícia na liečenie demyelizačných ochorení a paralýzy podávaním remyelizačných látok
SI1797109T1 (sl) 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
KR20170123354A (ko) 2009-08-20 2017-11-07 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013541010A (ja) 2010-10-11 2013-11-07 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3603764B1 (de) * 2015-04-28 2022-03-30 Hybio Pharmaceutical Co., Ltd. Hochleistungsflüssigchromatografieverfahren
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
PL193300B1 (pl) 2007-01-31
DE69837324D1 (de) 2007-04-26
BR9807076B1 (pt) 2013-10-29
JP4216342B2 (ja) 2009-01-28
IL119989A0 (en) 1997-04-15
WO1998030227A1 (en) 1998-07-16
EA003128B1 (ru) 2003-02-27
CA2277365A1 (en) 1998-07-16
EP0975351B1 (de) 2007-03-14
AU5819598A (en) 1998-08-03
NZ336690A (en) 2001-05-25
EA199900621A1 (ru) 2000-02-28
ATE356608T1 (de) 2007-04-15
DE69837324T2 (de) 2007-11-29
BR9807076A (pt) 2000-05-02
EP0975351A4 (de) 2002-05-15
JP2001511121A (ja) 2001-08-07
HU226612B1 (en) 2009-04-28
HK1025737A1 (en) 2000-11-24
CZ297983B6 (cs) 2007-05-16
CN100528222C (zh) 2009-08-19
SK93199A3 (en) 2000-11-07
KR20000070058A (ko) 2000-11-25
BRPI9807076B8 (pt) 2021-05-25
AU737287B2 (en) 2001-08-16
PL334566A1 (en) 2000-03-13
CZ243799A3 (cs) 2000-06-14
HUP0001917A2 (hu) 2000-10-28
ZA98214B (en) 1999-08-11
CA2277365C (en) 2011-04-12
HUP0001917A3 (en) 2001-12-28
EP0975351A1 (de) 2000-02-02
IL130820A (en) 2007-03-08
CN1249690A (zh) 2000-04-05

Similar Documents

Publication Publication Date Title
SK284029B6 (sk) Farmaceutická kompozícia na liečenie roztrúsenej sklerózy
US6214791B1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1998030227A9 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP3712260B2 (ja) 自己免疫疾患のバイスタンダー抑制
AU742970B2 (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease
CN106668852B (zh) 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
EP1796710A2 (de) Kombinationstherapie mit glatirameracetat und n-acetylcystein zur behandlung von multipler sklerose
JP2527749B2 (ja) 移植拒否反応抑制または自己免疫疾患治療用薬学的組成物
EP2523668A1 (de) Behandlung multipler sklerose
US9089509B2 (en) Method of treatment of age-related macular degeneration
AU2003250892A1 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
RU2647438C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
HUT74900A (en) Treatment of autoimmune disease using oral tolerization and/or type i interferon
Hayashi et al. Protective role of nitric oxide in ocular toxoplasmosis.
KR100435040B1 (ko) 티세포매개성질환들의치료를위한제제들및방법들
Sela Immunomodulatory vaccines against autoimmune diseases
US8349314B2 (en) Method of treating and/or preventing type II diabetes using Actinomycetales
EP4353234A1 (de) Verwendung einer pyrrolopyrimidinverbindung
MXPA99006457A (en) Treatment of multiple sclerosisthrough ingestion or inhalation of copolymer-1
WO2023037160A2 (ru) Набор и разовая дозированная форма для профилактики сахарного диабета 1 типа, их применение для профилактики сахарного диабета 1 типа. способ профилактики сахарного диабета 1 типа у здоровых людей из группы высокого риска
AU2772702A (en) Method of suppressing beta-amyloid-related changes in Alzheimer's disease

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180112